Cost Effectiveness of a Human Papillomavirus Vaccine in reducing the risk of cervical cancer in Ireland using a transmission dynamic model. Cara Usher.

Slides:



Advertisements
Similar presentations
Overview of HPV vaccination Training GardasilTM
Advertisements

Mark Jit Modelling and Economics Unit Health Protection Agency, London Case study: Structural uncertainty in human papillomavirus vaccination modelling.
Cervical Screening and HPV testing
National Institute for Public Health and the Environment Comparison of network models for STI transmission and intervention: how useful are they for public.
Introduction Women experience distress and heightened anxiety in relation to further diagnostic evaluation of pre-cancerous cell changes of the cervix,
HPV Vaccine Update Eileen Yamada, MD, MPH Immunization Branch California Department of Health Services.
MS&E 220 Project Yuan Xiang Chew, Elizabeth A Hastings, Morris Jinhui Zhang Probabilistic Analysis of Cervical Cancer Screening and Vaccination.
A Cost-Effectiveness Analysis of Alternative Human papillomavirus ( HPV) Vaccination Strategies Elamin H. Elbasha Merck Research Laboratories, USA.
Economic evaluation of outcomes: long term primary and surrogate endpoints Dr. Giampiero Favato presented at the University Program in Health Economics.
Spotlight on Cervical Cancer Screening
HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA Roger J Rand.
The HPV Vaccine: Protecting Girls from Cervical Cancer
Presents: Erika Schwartz, MD Truth Times Two The Cervical Cancer (HPV) and Swine Flu Vaccines This webinar series is paid for fully by.
The HPV Vaccine Our Best Shot to Prevent Cervical Cancer Harold C. Wiesenfeld, MD,CM Department of Obstetrics, Gynecology and Reproductive Sciences-University.
What is HPV? Estimated to be the most common sexually transmitted infection in the United States.
Anticipated impact on HPV infection from HPV vaccination programs – cause for optimism Dr Paddy Horner.
Jennifer S. Smith University of North Carolina Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical.
Sharp L, Tilson L, Whyte S, Ó Céilleachair A
November 2005 Guy Hayhurst Consultant in Public Health, Eastern Cheshire PCT OVERVIEW OF THE CERVICAL SCREENING PROGRAMME.
Educational Module Cervical Cancer Screening.  Estimated new cases: 610  Estimated deaths: 150 Regular Pap tests combined with the HPV vaccine can.
HPV Vaccine – Does it Prevent Cervical Cancer?
HPV Vaccination - the end of the road for cervical cancer? Alison Fiander Wales College of Medicine Cardiff University.
HPV: How to prevent your patients from becoming my patients Katina Robison, MD Assistant Professor, Department of Obstetrics & Gynecology Director of Colposcopy.
A Cervical Cancer Decision Model to Inform Recommendations About Preventive Services Perspective of the Decision Modeler Shalini Kulasingam, PhD Duke University.
HPV and Cervical Cancer Screening and Prevention.
Bayesian Modelling for Clinical Decision Support: Cervical Cancer Screening1/31 University of Pittsburgh Medical Center (UPMC) Magee-Womens Hospital (MWH)
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Immunisation Against Human Papilloma Virus David Green – Immunisation Co- ordinator and Infection Control Nurse.
Women’s First Health Center Drs. Sylvester, Youngren, Lo and Sansobrino What You Should Know About Cervical Cancer: Part one in a series of four updates.
What Is HPV? Human Papillomaviruses have an icosahedral shape, contain DNA, and are non-enveloped There are at least 100 different types of HPV Over 30.
ADOLESCENT IMMUNIZATIONS
Epidemiology of a Chronic Disease Exercise By Mary Murphy April 2008
HPV Related Disease Ginny Ryan. What Is HPV? The human papillomavirus is the most common sexually transmitted infection in the U.S. – 79 million Americans.
HPV Immunisation update 1.Update on the programme 2.Overview of Surveillance strategy 3.Details of proposed surveillance linked to the cervical screening.
An Overview of Cervical Cancer jfsdfkjsdlfjhs Naomi Brewer The Future of Cancer Screening in New Zealand Balancing the benefits and risks Auckland, 7 August.
Herpes Papillomavirus (HPV) and Varicella-zoster Virus (VZV) Vaccination Ellen Barbouche, MD Primary Care Conference 18 April 2007.
Facts and Prevention Presented By: Ashley Austin-Yearwood, John Cyril Quarshie, Lauren Decker, Jamison Halliwell.
HPV VACCINATION Dr Frida Mghamba 2 nd East Africa WE CAN Summit 11 th September 2014.
Supporting tough decisions: linking Health technology assessment (HTA) and national priority setting in Norway Ånen Ringard 1, Berit Mørland 1,2 1 Secretariat.
The HPV Vaccine: Protecting Your Daughter from Cervical Cancer Your questions deserve trusted answers.
Cervical Cancer. Female Gynecologic Cancers Cervical Cancer.
By, Acchaya Bajracharya & Veronika Putzenlechner.
Source: projectaccept.org. Did you know… HPV is the most common sexually transmitted infection in the U.S. Nearly all sexually active people will get.
Position on HPV vaccinesAvailable from In July 2013, The Global Advisory Committee on Vaccine Safety (GACVS) of the WHO reconfirmed that there had been.
Cervical Cancer How We Can Prevent It Dr Quek Swee Chong Himalayan Women’s Health Project 30 August 2014.
What you need to know about cervical cancer. Cervical Cancer Statistics  United States  An estimated 12,000 new cases each year  An estimated 4,000.
HPV-related anogenital cancers
Dacy Gaston NSG  According to the CDC (2014)  “Human papillomavirus (pap-ah-LO-mah-VYE-rus) (HPV) is the most common sexually transmitted virus.
Mathematical modelling of male circumcision in sub-Saharan Africa predicts significant reduction in HIV prevalence Greg Londish 1, John Murray 1,2 1 School.
Date of download: 6/26/2016 From: Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in.
“Take the Test: Not the Risk” HPV and Cervical Cancer Cervical Cancer is Preventable!
#AIDS2016 Cervical Cancer Prevention in Africa: The Future Nelly Yatich, DrPH University of California San Francisco July 19 th, 2016.
Cervical Screening- Implementation and local audit
Public Health England leads the NHS Screening Programmes
Cost-effectiveness Analysis for Cervical Cancer Screening Using HPV DNA Tests in Chile Franco Figueira S, BPharm student1; Cachoeira CV, MD, MBA1; Silva.
Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.
Cancers Linked to HPV Presenter: Chuck Lynch
Division of STD Prevention, CDC
Which social representations about cancer related to HPV infection and HPV vaccine from teenagers ? Charlotte Bauquier1 & Marie Préau12
HPV VACCINATION ——1st vaccine against cancer
Background & Objectives
HPV VACCINES Dr. Kirtan Krishna.
Nasreen Abdullah, MD, MPH
IAEN Conference (20 July 2018)
Public Health England leads the NHS Screening Programmes
Research Update: The HPV Vaccines
Epidemiology of cervical cancer in India: Where do we stand today
Presentation transcript:

Cost Effectiveness of a Human Papillomavirus Vaccine in reducing the risk of cervical cancer in Ireland using a transmission dynamic model. Cara Usher 1, Lesley Tilson 1, Cathal Walsh 2, Jens Olsen 3, Martin Rudbeck Jepsen 4, Michael Barry National Centre for Pharmacoeconomics, Dublin, Ireland. 2. Dept. of Statistics, Trinity College Dublin, Ireland. 3. University of Southern Denmark, Odense, Denmark. 4. Statens Serum Institut, Copenhagen, Denmark.

Aim To evaluate the cost effectiveness of a combined primary (vaccination) and secondary (screening) approach to managing pre-cancerous and cancerous lesions vs A population-based cervical cancer screening programme alone in Ireland.

Human Papilloma Virus (HPV) More than 100 different types of HPV infection have been characterised: –High risk – most common are HPV 16, 18, 45 and 31. –Low risk- include HPV types 6, 11. Cause ~70% of cervical cancers Cause ~ 90% of anogenital warts

Two vaccines currently developed: 1.Gardasil ® – protects against HPV types 16, 18, 6 and Cervarix ® – protects against HPV types 16 and 18. Efficacy demonstrated for up to 5.5 years after vaccination. Requirement for booster dose at later time not established. Routine cytology screening still required, as vaccines do not protect against all oncogenic types of HPV. Human Papilloma Virus (HPV) Vaccine

Natural history of HPV Normal Cervix Infection Clearance HPV infected Cervix (CIN 1) Progression Regression CIN 2/3 Cancer

Methods Framework Scope of analysis agreed with economic modelling group in Denmark and EAG in Ireland. Comparator Population-based cervical cancer screening programme Perspective Healthcare payer

Model Structure Transmission modelCost Effectiveness Model Simulated infection caused by HPV 16&18 only, using sexual behaviour patterns 1. HPV type-specific prevalence -Artistic trial 2. Calibration: Estimates CIN1-3, CC incidence 1.Layte et al, Kitchener et al, Outputs from transmission model combined with resource use and cost data Incremental effects ( incidence CIN 1-3, CC) Incremental costs (costs of vaccination vs no vaccination)

Model Inputs Epidemiological data Sexual behaviour patterns HPV-type distribution Prevalence of HPV infection Incidence of premalignant and invasive CC Resource use data Vaccination costs Direct medical costs Unit cost data

Model Inputs Time Horizon 70 yrs (9 – 79 years) Outcome Measure Life Years Gained Vaccine Coverage 80% (based on Men C catch-up programme). Discounting 3.5% costs & benefits

ScenarioCoverage 12 yr old females 80% 12 yr olds + catch-up to 15 yrs 80% 12 yr olds + catch-up to 17 yrs 80% 12 yr olds + catch-up to 19 yrs 80% 12 yr olds + catch-up to 26 yrs 80% 30% (GP)

Model Inputs (Summary) Vaccine efficacy95.2% Duration of vaccine protectionLifelong Screening25-44 yrs, 80% screened every 3 yrs yrs, 80% screened every 5 yrs Proportion of CIN 1-3 caused by HPV 16 & 18 74% CC 50% CIN 2/3, 35% CIN 1 Cost of vaccine€100 Administration costs€30 (<19 yrs) €58 (>19 yrs) Direct Medical Costs CIN 1 CIN 2/3 Invasive cancer €617 €1,632 €18,160 Discount Rate3.5% (costs & benefits)

ParameterOne-Way SAProbabilistic SA Vaccine Efficacy88% - 99%Beta (35, 2) Duration of vaccine protection10 yrs/booster Bernoulli (0, 5) Vaccine Coverage60%Beta (20, 5) Screening62%Beta (20, 5) Proportion of CIN 1-3 and CC caused by HPV 16 / 18 60% CC 40% CIN 2/3 21% CIN 1 Beta (60, 20) CC CIN 2/3 in proportion CIN 1 Cost of vaccine (per dose)€80 - €120 N (100, 10) Administration costs (per dose)€15 - €45N(30, 7) truncated to be +ive Direct Medical Costs  20%  N (0, 0.1) Discount rate0 and 6%Triangular (0, 3.5, 6%)

Results (1) – Simulation Model

Results (2) – Cases Averted Health state Estimated total number of cases in 2004 Average annual number of cases averted due to HPV vaccination CIN 17,2592,245 CIN2/33,5151,435 Cervical cancer Deaths from cervical cancer 9352

Results (3) – Cost Effectiveness of the base-case vaccination programme (HPV vaccination & screening vs screening alone) Incremental costs (discounted) Incremental life years gained (discounted) ICER € 6,984, years€ 17,383 / LYG

Results (3) – Cost Effectiveness of catch-up vaccination programmes ICER €17,383/LYG ICER €18,893/LYG ICER €20,646/LYG ICER €22,038/LYG ICER €24,534/LYG 12 yr olds + Catch-Up to 15 yrs: ICER €52,968/LYG.

Results (4) – Sensitivity Analysis: Probabilistic 2.5 centile 97.5 centile

Results (5) – Sensitivity Analysis: One-Way €17,383/LYG

Summary Cost-effectiveness of base-case vaccination programme ICER €17,383/LYG Cost-effectiveness of catch-up vaccination programmes ICER €52,968/LYG (12-15 yr olds)

Strengths / Limitations Study framework, i.e. a collaborative approach to assessing cost-effectiveness of an intervention in a short timeframe. Uncertainty with data. cross-protection requirement for booster vaccine efficacy against types 6 & 11

Conclusions Epidemiological impact of vaccination Cost effective to vaccinate 12 yr old females Cost effective to vaccinate 12 – 15 yr old females

Minister for Health Approves Introduction Of Cervical Cancer Vaccination Programme 5 th August 2008 “It is clear the main priority now is to move to the introduction of the vaccination programme for 12 year old girls to commence in September 2009”.

Acknowledgements